Madrigal Pharmaceuticals Inc (MDGL)
207.15
-0.89
(-0.43%)
USD |
NASDAQ |
May 09, 16:00
207.24
+0.09
(+0.04%)
After-Hours: 20:00
Madrigal Pharmaceuticals Cash from Financing (Quarterly): 573.71M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 573.71M |
| December 31, 2023 | 479.92M |
| September 30, 2023 | 19.58M |
| June 30, 2023 | 42.93M |
| March 31, 2023 | 52.69M |
| December 31, 2022 | 264.34M |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 49.11M |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 19.50M |
| September 30, 2021 | 21.10M |
| June 30, 2021 | 63.54M |
| March 31, 2021 | 67.09M |
| December 31, 2020 | 4.629M |
| September 30, 2020 | 0.35M |
| June 30, 2020 | 0.109M |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.035M |
| June 30, 2019 | 0.117M |
| March 31, 2019 | 0.083M |
| December 31, 2018 | 0.61M |
| September 30, 2018 | 0.451M |
| June 30, 2018 | 313.01M |
| March 31, 2018 | 0.265M |
| Date | Value |
|---|---|
| December 31, 2017 | 135.53M |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 34.88M |
| March 31, 2017 | 3.399M |
| December 31, 2016 | 5.954M |
| September 30, 2016 | 1.625M |
| June 30, 2016 | 6.125M |
| March 31, 2016 | 0.75M |
| December 31, 2015 | 1.35M |
| September 30, 2015 | -35.24M |
| June 30, 2015 | 39.50M |
| March 31, 2015 | -2.311M |
| December 31, 2014 | -2.309M |
| September 30, 2014 | 25.82M |
| June 30, 2014 | 54.17M |
| March 31, 2014 | 7.617M |
| December 31, 2013 | 56.85M |
| September 30, 2013 | -0.211M |
| June 30, 2013 | 0.12M |
| March 31, 2013 | 12.28M |
| December 31, 2012 | 58.07M |
| September 30, 2012 | 23.95M |
| June 30, 2012 | 0.441M |
| March 31, 2012 | 33.05M |
| December 31, 2011 | -0.069M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
Dec 2019
573.71M
Maximum
Mar 2024
82.94M
Average
19.54M
Median
Cash from Financing (Quarterly) Benchmarks
| Eli Lilly and Co | -311.30M |
| Viking Therapeutics Inc | 606.04M |
| Akero Therapeutics Inc | 0.502M |
| 89bio Inc | 162.17M |
| Geron Corp | 147.80M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -149.16M |
| Cash from Investing (Quarterly) | 98.05M |
| Free Cash Flow | -391.12M |
| Free Cash Flow Per Share (Quarterly) | -7.475 |
| Free Cash Flow Yield | -9.86% |